Literature DB >> 18652601

Probability that a two-stage genome-wide association study will detect a disease-associated snp and implications for multistage designs.

M H Gail1, R M Pfeiffer, W Wheeler, D Pee.   

Abstract

Large two-stage genome-wide association studies (GWASs) have been shown to reduce required genotyping with little loss of power, compared to a one-stage design, provided a substantial fraction of cases and controls, pi(sample), is included in stage 1. However, a number of recent GWASs have used pi(sample) < 0.2. Moreover, standard power calculations are not applicable because SNPs are selected in stage 1 by ranking their p-values, rather than comparing each SNP's statistic to a fixed critical value. We define the detection probability (DP) of a two-stage design as the probability that a given disease-associated SNP will have a p-value among the lowest ranks of p-values at stage 1, and, among those SNPs selected at stage 1, at stage 2. For 8000 cases and 8000 controls available for study and for odds ratios per allele in the range 1.1-1.3, we show that DP is substantially reduced for designs with pi(sample)<or= 0.25, and that DP cannot be appreciably increased by analyzing the stage 1 and stage 2 data jointly. These results suggest that multistage designs with small first stages (e.g. pi(sample)<or= 0.25) should be avoided, and that additional genotyping in earlier studies with small first stages will yield previously unselected disease-associated SNPs.

Entities:  

Mesh:

Year:  2008        PMID: 18652601      PMCID: PMC2574571          DOI: 10.1111/j.1469-1809.2008.00467.x

Source DB:  PubMed          Journal:  Ann Hum Genet        ISSN: 0003-4800            Impact factor:   1.670


  15 in total

1.  Genomic control for association studies.

Authors:  B Devlin; K Roeder
Journal:  Biometrics       Date:  1999-12       Impact factor: 2.571

2.  Sample size calculations for population- and family-based case-control association studies on marker genotypes.

Authors:  Ruth M Pfeiffer; Mitchell H Gail
Journal:  Genet Epidemiol       Date:  2003-09       Impact factor: 2.135

3.  Ranks of genuine associations in whole-genome scans.

Authors:  Dmitri V Zaykin; Lev A Zhivotovsky
Journal:  Genetics       Date:  2005-07-14       Impact factor: 4.562

4.  Optimal two-stage genotyping designs for genome-wide association scans.

Authors:  Hansong Wang; Duncan C Thomas; Itsik Pe'er; Daniel O Stram
Journal:  Genet Epidemiol       Date:  2006-05       Impact factor: 2.135

5.  Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies.

Authors:  Andrew D Skol; Laura J Scott; Gonçalo R Abecasis; Michael Boehnke
Journal:  Nat Genet       Date:  2006-01-15       Impact factor: 38.330

6.  A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease.

Authors:  Stephan Buch; Clemens Schafmayer; Henry Völzke; Christian Becker; Andre Franke; Huberta von Eller-Eberstein; Christian Kluck; Ingelore Bässmann; Mario Brosch; Frank Lammert; Juan Francisco Miquel; Flavio Nervi; Michael Wittig; Dieter Rosskopf; Birgit Timm; Christine Höll; Marcus Seeger; Abdou ElSharawy; Tim Lu; Jan Egberts; Fred Fändrich; Ulrich R Fölsch; Michael Krawczak; Stefan Schreiber; Peter Nürnberg; Jürgen Tepel; Jochen Hampe
Journal:  Nat Genet       Date:  2007-07-15       Impact factor: 38.330

7.  From genotypes to genes: doubling the sample size.

Authors:  P D Sasieni
Journal:  Biometrics       Date:  1997-12       Impact factor: 2.571

8.  Two-stage designs for gene-disease association studies with sample size constraints.

Authors:  Jaya M Satagopan; E S Venkatraman; Colin B Begg
Journal:  Biometrics       Date:  2004-09       Impact factor: 2.571

9.  Two-stage designs for gene-disease association studies.

Authors:  Jaya M Satagopan; David A Verbel; E S Venkatraman; Kenneth E Offit; Colin B Begg
Journal:  Biometrics       Date:  2002-03       Impact factor: 2.571

10.  Optimal two-stage genotyping in population-based association studies.

Authors:  Jaya M Satagopan; Robert C Elston
Journal:  Genet Epidemiol       Date:  2003-09       Impact factor: 2.135

View more
  7 in total

1.  Using Ascertainment for Targeted Resequencing to Increase Power to Identify Causal Variants.

Authors:  M D Swartz; B Peng; C Reyes-Gibby; S Shete
Journal:  Stat Interface       Date:  2011       Impact factor: 0.582

Review 2.  Validating, augmenting and refining genome-wide association signals.

Authors:  John P A Ioannidis; Gilles Thomas; Mark J Daly
Journal:  Nat Rev Genet       Date:  2009-05       Impact factor: 53.242

3.  Invited Commentary: E Pluribus Unum for Epidemiology.

Authors:  Sophia S Wang; James V Lacey
Journal:  Am J Epidemiol       Date:  2015-12-10       Impact factor: 4.897

4.  Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies.

Authors:  Steven J Skates; Michael A Gillette; Joshua LaBaer; Steven A Carr; Leigh Anderson; Daniel C Liebler; David Ransohoff; Nader Rifai; Marina Kondratovich; Živana Težak; Elizabeth Mansfield; Ann L Oberg; Ian Wright; Grady Barnes; Mitchell Gail; Mehdi Mesri; Christopher R Kinsinger; Henry Rodriguez; Emily S Boja
Journal:  J Proteome Res       Date:  2013-10-28       Impact factor: 4.466

5.  Regionally Smoothed Meta-Analysis Methods for GWAS Datasets.

Authors:  Ferdouse Begum; Monir H Sharker; Stephanie L Sherman; George C Tseng; Eleanor Feingold
Journal:  Genet Epidemiol       Date:  2015-12-28       Impact factor: 2.135

6.  False discovery rate control in two-stage designs.

Authors:  Sonja Zehetmayer; Martin Posch
Journal:  BMC Bioinformatics       Date:  2012-05-06       Impact factor: 3.169

7.  Improved minimum cost and maximum power two stage genome-wide association study designs.

Authors:  Stephen A Stanhope; Andrew D Skol
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.